ESPR FY 2024 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

FY 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$332M+185.7% YoY

Gross Profit

$264M79.4% margin

Operating Income

$54M16.4% margin

Net Income

-$52M-15.6% margin

EPS (Diluted)

$-0.28

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$344M

Total Liabilities

$733M

Stockholders' Equity

-$389M

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$332M	$116M	+185.7%
Gross Profit	$264M	$73M	+260.9%
Operating Income	$54M	-$156M	+135.0%
Net Income	-$52M	-$209M	+75.3%